ClinicalTrials.Veeva

Menu

Changes in the Blood-brain Barrier During Maintenance ECT in Formerly Depressed Patients (3BECT)

University of Copenhagen logo

University of Copenhagen

Status

Completed

Conditions

Depression

Study type

Observational

Funder types

Other

Identifiers

NCT05820230
H-22039168

Details and patient eligibility

About

The aim of the study is to examine the effect of electroconvulsive therapy (ECT) on the blood-brain barrier (BBB) in patients who had suffered from depression. We will study the BBB with dynamic contrast enhanced (DCE) MRI before and after treatment with a single ECT in patients currently undergoing ECT. The study is an observational (naturalistic) longitudinal study.

Full description

Primary hypothesis

  1. The BBB permeability to Gadovist (measured as Ki) temporarily increases in the right and left hippocampus (HC) after a single ECT.

    Secondary hypothesises

  2. The volume of the right and left HC increases after a single ECT and the volume increase is positively correlated with the BBB permeability

  3. A larger post-ECT increase in systolic blood pressure correlates with a larger increase in BBB permeability in the right and left HC.

  4. A larger increase in serum S100-B compared to baseline values is correlated with increased BBB permeability in the right and left HC.

Enrollment

7 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • We will include patients (age 18-75) currently treated with a series of ECT or maintenance ECT referred to the treatment due to moderate to severe depression according to ICD-10.

Exclusion criteria

  1. Schizophrenia
  2. Psychotic symptoms
  3. Any substance use (other than cigarette smoking and alcohol consumption within the recommendations of the Danish National Health Authority) within the last 3 months
  4. Risk of suicide making transport or participation in the study hazardous
  5. Claustrophobia or severe restlessness
  6. Contraindications to DCE-MRI (e.g., metallic implants, increased body temperature, reduced kidney function (estimated Global Filtration Rate (eGFR) of <40 ml/min/1.73 m2), pregnancy)
  7. Somatic illness potentially confounding results (e.g., any central nervous system diseases or cancers)
  8. Lack of consent to being informed of potential medically important findings on MRI or blood tests

Trial contacts and locations

1

Loading...

Central trial contact

Christoffer Lundsgaard

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems